Phase 2
Who we are
A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer
Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
Phase 2 Study of DKN-01 in Colorectal Cancer
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
